Belen Garijo, the CEO of Merck KGaA, says focus on growth and innovation is key to the German group’s future.

We recently compiled a list of the 7 Blue Chip Stocks with Low PE Ratios. In this article, we are going to take a look at ...

It hasn't been the best quarter for Merck & Co., Inc. ( NYSE:MRK ) shareholders, since the share price has fallen ...

We recently compiled a list of 10 Most Promising Long-Term Stocks According to Hedge Funds. In this article, we will look at ...

On Wednesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $110.42 which represents a decrease of $-1.11 or -1.00% from the prior close of $111.53. The stock opened at $111 and touched ...

Highlights:,Merck & Co Inc's experimental treatment, clesrovimab, has demonstrated positive results in a mid- to late-stage ...

Merck said the Phase 2b/3 pivotal study evaluating a single dose of clesrovimab administered to healthy preterm and full-term infants met all prespecified endpoints, with consistent results through ...

Merck announces positive results from Phase 2b/3 and interim Phase 3 trials of a monoclonal antibody designed to protect infants from RSV.

Merck Foundation in partnership with African First Ladies and Ministries of Health and Medical Societies provided out of total 2080 Scholarships, 830 Scholarships of one-year Post-Graduate Diploma and ...

Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high ...

Clesrovimab (MK-1654), an Investigational RSV Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and ...

Merck & Co., Inc. (MRK) announced the positive results from the Phase 2b/3 clinical trial (MK-1654-004) evaluating clesrovimab, the ...